Two Novel and Three Recurrent Mutations in the Mevalonate Pathway Genes in Chinese Patients with Porokeratosis
Xiuping Wang,Xiaoliang Ouyang,Deng Zhang,Yunxia Zhu,Liang Wu,Zhen Xiao,Simin Yu,Wei Li,Chunming Li
DOI: https://doi.org/10.2147/ccid.s444985
2024-01-25
Clinical Cosmetic and Investigational Dermatology
Abstract:Xiuping Wang, 1 Xiaoliang Ouyang, 2 Deng Zhang, 1 Yunxia Zhu, 1 Liang Wu, 1 Zhen Xiao, 3 Simin Yu, 1 Wei Li, 2 Chunming Li 1 1 Department of Dermatology, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, People's Republic of China; 2 Department of Plastic Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, People's Republic of China; 3 Department of Dermatology, Taiyuan Central Hospital, Taiyuan, Shanxi, People's Republic of China Correspondence: Chunming Li, Department of Dermatology, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, People's Republic of China, Tel/Fax +86 791 86278821, Email Purpose: Porokeratosis (PK) is a chronic autosomal-dominant cutaneous keratinization disorder exhibiting clinical and genetic heterogeneity. Mevalonate decarboxylase ( MVD ), farnesyl diphosphate synthase ( FDPS ), phosphomevalonate kinase( PMVK ), and mevalonate kinase genes( MVK ), which encode the mevalonate pathway, are disease-causing genes in PK. Patients and Methods: Data and blood samples were collected from two Chinese families and five sporadic patients with porokeratosis. Whole-exome and Sanger sequencing were performed to detect pathogenic gene mutation in the patients. Results: Five heterozygous mutations were identified, including a novel FDPS stop-gain mutation c.438T>G (p.Tyr146Ter), a novel MVD missense mutation c.683G>C (p.R228P), and three previously reported MVD mutations: c.746T>C (p.F249S), c.875A>G (p.N292S), and c.1111_1113del (p.371_371del). The novel FDPS c.438T>G mutation was predicted as "disease-causing" (p = 1) by Mutation Taster. The other novel MVD c.683G>C was also predicted as "deleterious" (score = 0.00) by Sorting Intolerant From Tolerant (SIFT), "probably damaging" (score = 1) by PolyPhen2, and "disease-causing" (p = 0.999) by Mutation Taster. Conclusion: Our results extended the mutation spectrum of mevalonate pathway genes in porokeratosis and provided useful strategies for a more accurate diagnosis and genetic counseling. Keywords: porokeratosis, mutation, MVD , FDPS , genetics Porokeratosis (PK; OMIM 175800) is a rare, clinically, and genetically heterogeneous disorder with abnormal epidermal differentiation that exhibits autosomal dominant inheritance. PK manifests as sharply demarcated hyperkeratotic papules and plaques with prominent peripheral ridging and central atrophy. Histologically, this characteristic feature is called the cornoid lamella, which is a column of parakeratotic cells in the epidermis. Based on the distribution and morphology of the lesions, PK is classified into several clinical variants, including disseminated superficial porokeratosis (DSP), linear porokeratosis (LP), disseminated superficial actinic porokeratosis (DSAP), porokeratosis of Mibelli (PM), and porokeratosis palmaris, plantaris, and disseminata (PPPD). Several rare clinical types, such as giant porokeratosis, porokeratosis ptychotropica, and punctate porokeratosis (PP), have also been reported. 1,2 LP is at a certain risk of cancerous transformation into squamous or basal cell carcinoma. 3,4 Four mevalonate pathway genes, including farnesyl diphosphate synthase ( FDPS ), mevalonate decarboxylase ( MVD ), phosphomevalonate kinase ( PMVK ), and mevalonate kinase ( MVK ) are PK disease-causing genes. 3,5 We performed whole-exome sequencing (WES) and Sanger sequencing to explore the pathogenic mutations in two Chinese families and five sporadic cases of porokeratosis. In addition, the pathogenicity was predicted via bioinformatics analysis. Data and blood samples were collected from two Chinese families (one DSAP and DSP) and five sporadic cases (three DSP and two LP) between September 2021 and October 2022. PK was diagnosed based on clinical presentation and histological examination. All procedures were approved by the Ethics Committee of the Second Affiliated Hospital of Nanchang University. Approximately 5 mL of peripheral blood or 1 mL of saliva was collected from the participants. Written informed consent was obtained. Probands from two Chinese families and five patients with sporadic PK were selected for WES. DNA was isolated from peripheral blood, and a whole-exome library was constructed. Subsequently, a HiSeq 2000 Sequencing System (Illumina, San Diego, CA, USA) was used to perform a 2×150 bp paired-end massively parallel sequencing. Finally, Single Nucleotide Variants (SNVs) were filtered, and their functional effects were assessed by Mutatio -Abstract Truncated-
dermatology